• 1
    Evans RM, Amara S, Rosenfield MG. Molecular events in developmental regulation of neuroendocrine genes: characterization of the novel neuropeptide CGRP. Cold Spring Harb Symp Quant Biol 1983; 48: 4137.
  • 2
    Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985; 313: 546.
  • 3
    Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett 1985; 58: 2137.
  • 4
    Uddman R, Edvinsson L, Ekblad E, Håkanson R, Sundler F. Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 1986; 15: 123.
  • 5
    De Hoon JN, Pickkers P, Smits P, Struijker-Boudier HA, Van Bortel LM. Calcitonin gene-related peptide: exploring its vasodilating mechanism of action in humans. Clin Pharmacol Ther 2003; 73: 31221.
  • 6
    Edvinsson L, Hargreaves R. CGRP involvement in migraines. In: The Headaches, 3rd edn, ed. OlesenJ. Philadelphia, PA: Lippincott Williams & Wilkins Publishing, 2006; 289300.
  • 7
    Goadsby PJ. Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era? Neurology 2008; 70: 13001.
  • 8
    Sexton PM. Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol Neurobiol 1991; 5: 25173.
  • 9
    Christopoulos G, Sexton P, Paxinos G, Huang X-F, Beaumont K, Toga A. Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain. Can J Physiol Pharmacol 1995; 73: 103741.
  • 10
    Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990; 28: 1837.
  • 11
    Ma QP, Hill R, Sirinathsinghji D. Colocalization of CGRP with 5-HT1B/1D receptors and substance P in trigeminal ganglion neurons in rats. Eur J Neurosci 2001; 13: 2099104.
  • 12
    Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U, Pollentier S, Lesko LM. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 110410.
  • 13
    Hershey JC, Corcoran HA, Baskin EP, Salvatore CA, Mosser S, Williams TM, Koblan KS, Hargreaves RJ, Kane SA. Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist using a novel pharmacodynamic assay. Regul Pept 2005; 127: 717.
  • 14
    Van der Schueren BJ, De Hoon JN, Vanmolkot FH, Van Hecken A, Depre M, Kane SA, De Lepeleire I, Sinclair SR. Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging. Br J Clin Pharmacol 2007; 64: 58090.
  • 15
    Van der Schueren BJ, Rogiers A, Vanmolkot FH, Van Hecken A, Depré M, Kane SA, De Lepeleire I, Sinclair SR, De Hoon JN. Calcitonin gene-related peptide8-37 antagonizes capsaicin-induced vasodilation in the skin: evaluation of a human in vivo pharmacodynamic model. J Pharmacol Exp Ther 2008; 325: 24855.
  • 16
    Paone DV, Shaw AW, Nguyen DN, Burgey CS, Deng JZ, Kane SA, Koblan KS, Salvatore CA, Mosser SD, Johnston VK, Wong BK, Miller-Stein CM, Hershey JC, Graham SL, Vacca JP, Williams TM. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 2007; 50: 55647.
  • 17
    Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW, Graham SL, Vacca JP, Williams TM, Koblan KS, Kane SA. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008; 324: 41621.
  • 18
    Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 130412.
  • 19
    Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 211523.
  • 20
    Connor K, Shapiro R, Diener H-C, Lucas S, Kost J, Fan X, Fei K, Assaid C, Lines C, Ho TW. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009; 73: 9707.
  • 21
    Han TH, Blanchard R, Palcza J, De Lepeleire I, Laethem M, Martucci A, Willson K, Xu Y, Boyle J, Butterfield K, Mahon C, Lewis N. The pharmacokinetics, safety and tolerability of telcagepant, a novel calcitonin gene related peptide (CGRP) receptor antagonist, in healthy subjects and migraineurs. Clin Pharmacol Ther 2009; 85 (Suppl. 1): S3940.Abstract PII-11.
  • 22
    Fullerton A, Stücker M, Wilhelm KP, Wårdell K, Anderson C, Fischer T, Nilsson GE, Serup J; European Society of Contact Dermatitis Standardization Group. Guidelines for visualization of cutaneous blood flow by laser Doppler perfusion imaging. A report from the Standardization Group of the European Society of Contact Dermatitis based upon the HIRELADO European community project. Contact Dermatitis 2002; 46: 12940.
  • 23
    Xu Y, Willson KW, Anderson MDG, Miller-Stein CM, Woolf EJ. Elimination of diastereomer interference to determine Telcagepant (MK-0974) in human plasma using on-line turbulent-flow technology and off-line solid-phase extraction coupled with liquid chromatography/tandem mass spectrometry. J Chromatogr B 2009; 877: 163442.
  • 24
    Denney WS, Hang Y, Dockendorf MF, Li C-C, Eid SR, Valesky R, Laethem T, Van Hoydonck P, De Lepeleire I, De Hoon JNJM, Crutchlow M, Blanchard R. Modeling and simulation for determination of the therapeutic window of MK-2295: a TRPV1 antagonist. PAGE 18 (2009) Abstract 1507. Available at (last accessed 2 October, 2009).
  • 25
    Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, Eberlein W. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000; 129: 4203.
  • 26
    Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. Cephalalgia 2004; 24: 64556.
  • 27
    Wallengren J. Vasoactive peptides in the skin. J Investig Dermatol Symp Proc 1997; 2: 4955.
  • 28
    Grant AD, Gerard NP, Brain SD. Evidence of a role for NK1 and CGRP receptors in mediating neurogenic vasodilatation in the mouse ear. Br J Pharmacol 2002; 135: 35662.
  • 29
    Gardiner SM, Compton AM, Kemp PA, Bennett T, Bose C, Foulkes R, Hughes B. Human alpha-calcitonin gene-related peptide (CGRP)-(8-37), but not -(28-37), inhibits carotid vasodilator effects of human alpha-CGRP in vivo. Eur J Pharmacol 1991; 199: 3758.
  • 30
    Arulmani U, Schuijt MP, Heiligers JP, Willems EW, Villalón CM, Saxena PR. Effects of the calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS on alpha-CGRP-induced regional haemodynamic changes in anaesthetised rats. Basic Clin Pharmacol Toxicol 2004; 94: 2917.
  • 31
    Kapoor K, Arulmani U, Heiligers JP, Willems EW, Doods H, Villalón CM, Saxena PR. Effects of BIBN4096BS on cardiac output distribution and on CGRP-induced carotid haemodynamic responses in the pig. Eur J Pharmacol 2003; 475: 6977.
  • 32
    Shen YT, Pittman TJ, Buie PS, Bolduc DL, Kane SA, Koblan KS, Gould RJ, Lynch JJ Jr. Functional role of alpha-calcitonin gene-related peptide in the regulation of the cardiovascular system. J Pharmacol Exp Ther 2001; 298: 5518.
  • 33
    Vanmolkot FH, Van der Schueren BJ, De Hoon JN. Calcitonin gene-related peptide-induced vasodilation in the human forearm is antagonized by CGRP8-37: evaluation of a human in vivo pharmacodynamic model. Clin Pharmacol Ther 2006; 79: 26373.
  • 34
    Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L, Olesen J. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005; 25: 13947.
  • 35
    Mair J, Lechleitner P, Längle T, Wiedermann C, Dienstl F, Saria A. Plasma CGRP in acute myocardial infarction. Lancet 1990; 335: 168.
  • 36
    Gennari C, Nami R, Agnusdei D, Fischer JA. Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure. Cardiovasc Res 1990; 24: 23941.